BRPI0511885A - derivados de cromona úteis como antagonistas de vanilóide - Google Patents

derivados de cromona úteis como antagonistas de vanilóide

Info

Publication number
BRPI0511885A
BRPI0511885A BRPI0511885-9A BRPI0511885A BRPI0511885A BR PI0511885 A BRPI0511885 A BR PI0511885A BR PI0511885 A BRPI0511885 A BR PI0511885A BR PI0511885 A BRPI0511885 A BR PI0511885A
Authority
BR
Brazil
Prior art keywords
derivatives useful
chromone derivatives
vanilloid antagonists
antagonists
chromone
Prior art date
Application number
BRPI0511885-9A
Other languages
English (en)
Inventor
Timothy John Ritchie
Andrew James Culshaw
Christopher Thomas Brain
Edward Karol Dziadulewicz
Terance William Hart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0511885A publication Critical patent/BRPI0511885A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE CROMONA úTEIS COMO ANTAGONISTAS DE VANILóIDE. A presente invenção refere-se ao emprego de um composto de cromona da fórmula em que R~ 1~,R~ 2~,R~ 3~, R~ 4~, R~ 5~ e m são tais como definidos no relatório descritivo e nas reivindicações, na forma livre ou na forma de sal, e, onde possível, na forma de sal de adição ácido, como um antagonista de vanilólde.
BRPI0511885-9A 2004-06-08 2005-06-08 derivados de cromona úteis como antagonistas de vanilóide BRPI0511885A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0412768.4A GB0412768D0 (en) 2004-06-08 2004-06-08 Organic compounds
PCT/EP2005/006252 WO2005121116A1 (en) 2004-06-08 2005-06-08 Chromone derivatives useful as vanilloid antagonists

Publications (1)

Publication Number Publication Date
BRPI0511885A true BRPI0511885A (pt) 2008-01-15

Family

ID=32696853

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511885-9A BRPI0511885A (pt) 2004-06-08 2005-06-08 derivados de cromona úteis como antagonistas de vanilóide

Country Status (12)

Country Link
US (1) US20080114056A1 (pt)
EP (1) EP1756080A1 (pt)
JP (1) JP2008501762A (pt)
KR (1) KR100903713B1 (pt)
CN (1) CN1993344A (pt)
AU (1) AU2005251920A1 (pt)
BR (1) BRPI0511885A (pt)
CA (1) CA2569113A1 (pt)
GB (1) GB0412768D0 (pt)
MX (1) MXPA06014337A (pt)
RU (1) RU2006146630A (pt)
WO (1) WO2005121116A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0524808D0 (en) 2005-12-05 2006-01-11 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP5315590B2 (ja) * 2006-02-14 2013-10-16 Ｊｎｃ株式会社 液晶化合物、液晶組成物および液晶表示素子
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
CN101648959B (zh) * 2008-08-15 2011-05-11 巴塞利亚药业（中国）有限公司 香豆酮并色酮类化合物及其制备与应用
MX2011005147A (es) * 2008-11-17 2011-08-29 Glenmark Pharmaceuticals Sa Derivados de cromenona como antagonistas de trpv3.
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
CN103079558B (zh) 2010-04-05 2025-09-12 上海复星医药产业发展有限公司 IRE-1α抑制剂
JP2013527159A (ja) * 2010-04-23 2013-06-27 キネタ・インコーポレイテツド 抗ウイルス性化合物
EP2497458A1 (en) 2011-03-08 2012-09-12 B.R.A.I.N. Biotechnology Research And Information Network AG Small molecule modulators of the cold and menthol receptor TRPM8
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU162377B (pt) * 1970-05-27 1973-02-28
US3864362A (en) * 1970-05-27 1975-02-04 Chinoin Gyogyszer Es Vegyeszet Iso flavones
GB1495305A (en) * 1975-09-12 1977-12-14 Pfizer Ltd 3-phenyl-4-oxo-4h-benzopyran derivatives
US4501755A (en) * 1981-05-01 1985-02-26 Pennwalt Corporation Isoflavones useful as anti-inflammatory agents
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
HUT68558A (en) * 1993-07-20 1995-06-28 Chinoin Gyogyszer Es Vegyeszet Method for preparing isoflavon derivatives
IT1289154B1 (it) * 1997-01-03 1998-09-29 Chiesi Farma Spa Derivati di isoflavone loro preparazione e loro impiego terapeutico
GB9920912D0 (en) * 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
FR2815033B1 (fr) * 2000-10-06 2003-09-05 Negma Lab Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CA2569113A1 (en) 2005-12-22
JP2008501762A (ja) 2008-01-24
CN1993344A (zh) 2007-07-04
EP1756080A1 (en) 2007-02-28
WO2005121116A1 (en) 2005-12-22
MXPA06014337A (es) 2007-02-19
KR20070047280A (ko) 2007-05-04
KR100903713B1 (ko) 2009-06-19
US20080114056A1 (en) 2008-05-15
GB0412768D0 (en) 2004-07-07
AU2005251920A1 (en) 2005-12-22
RU2006146630A (ru) 2008-07-20

Similar Documents

Publication Publication Date Title
BRPI0818672B8 (pt) composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
ATE466002T1 (de) Substituierte benzo (d) isoaxol-3-yl-amin- verbindungen als analgetika
BR112013016595A2 (pt) inibidores de neprilisina
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
WO2007008704A3 (en) Melanocortin receptor ligands
NO20090295L (no) Substituerte heteroarylderivater
ECSP109968A (es) Depsipéptidos cíclicos
NO20083694L (no) Bruk av rylener som markorer for vaesker
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
ES2531093T3 (es) Procedimiento de preparación de halogenuros de N-alquil-naltrexona
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EA200970472A1 (ru) Замещенные пиразолы, композиции, их содержащие, способ получения и применение
WO2008009750A3 (en) Macrocyclic compounds useful as bace inhibitors
BRPI0411087A (pt) aperfeiçoamentos em ou relacionados a compostos orgánicos
BRPI0605926A2 (pt) ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos
MX2010002007A (es) Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace.
BRPI0415285A (pt) derivados de aminoalcanol
EA200901059A1 (ru) Макролиды на основе эритромицина
AR060155A1 (es) Combinaciones de principios activos con propiedades insecticidas y acaricidas

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.